Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Gastroenterology

Journal Scan / Research · November 06, 2024

Intensified- vs Standard-Dose Infliximab Induction Therapy for Steroid-Refractory Acute Severe Ulcerative Colitis

The Lancet Gastroenterology & Hepatology

 

Additional Info

The Lancet Gastroenterology & Hepatology
Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial
Lancet Gastroenterol Hepatol 2024 Nov 01;9(11)981-996, MC Choy, CFD Li Wai Suen, D Con, K Boyd, R Pena, K Burrell, O Rosella, D Proud, R Brouwer, A Gorelik, D Liew, WR Connell, EK Wright, KM Taylor, A Pudipeddi, M Sawers, B Christensen, W Ng, J Begun, G Radford-Smith, M Garg, N Martin, DR van Langenberg, NS Ding, L Beswick, RW Leong, MP Sparrow, P De Cruz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading